1. Scrip
  2. >>Business
  3. >>Strategy

Generate Snares Novartis As Partner/Investor For Its AI/ML Approach

 
• By Joseph Haas

Like a previous alliance with Amgen, Generate will use its technology to discover and develop computationally designed therapeutic proteins against multiple undisclosed targets.

Generate
Generate will partner with Novartis to discover novel protein therapeutics • Source: Shutterstock

Generative artificial intelligence firm Generate Biomedicines unveiled a novel protein discovery and development collaboration with Novartis AG on 24 September that it called part of an effort to ensure its technology helps as many patients as possible. Generate has previously partnered with Amgen, Inc. and is part of a pair of academic research alliances.

Key Takeaways

  • Generate Biomedicines will get $65m up front, including a $15m equity investment, from Novartis to use its generative AI platform to discover and develop novel proteins against undisclosed targets.

The Somerville, MA-based company will get $65m up front from Novartis, $15m of that comprising an equity stake, and can...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

More from Business

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

 
• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.